Transfidelity

Background

Project Transfidelity is developing a novel approach to target the root cause of neurodegenerative diseases like Alzheimer’s. Instead of treating symptoms, we aim to improve protein production accuracy and prevent toxic aggregates from forming in the first place.

Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience, the team has identified two molecules with the potential to protect against protein misfolding and cognitive decline. Cerebrum DAO will support the development of near- and long-term solutions for neurodegeneration and aging.
Project Transfidelity has the potential to lead in this fast-growing market by focusing on prevention rather than treatment. This IPT represents a new opportunity to create novel IP around protein fidelity and drive future studies aimed at addressing the underlying causes of aging and dementia.
‍

Commercial Potential

There is a high unmet need for effective treatments for neurodegenerative diseases and the growing prevalence of these conditions. Alzheimer's disease alone affects approximately 55 million people worldwide, with annual healthcare costs reaching $1.3 trillion. The final product of this research will be a small molecule to treat age-related neurodegenerative disorders like Alzheimer’s and Parkinson’s that would benefit from enhanced translation fidelity.
‍

Senior Review

The project was reviewed by four reviewers: a scientist, an entrepreneur, a VC, and a professor. The majority of the reviewers thought that this project is a moonshot. Two reviewers recommended that the project should be advanced for token-holders vote, one that it should be followed-up with the applicant for more information, one that it should be denied outright giving constructive feedback.

‍

‍